CA2204130A1 - Antagonistes de la tachykinine - Google Patents

Antagonistes de la tachykinine

Info

Publication number
CA2204130A1
CA2204130A1 CA002204130A CA2204130A CA2204130A1 CA 2204130 A1 CA2204130 A1 CA 2204130A1 CA 002204130 A CA002204130 A CA 002204130A CA 2204130 A CA2204130 A CA 2204130A CA 2204130 A1 CA2204130 A1 CA 2204130A1
Authority
CA
Canada
Prior art keywords
phenyl
hydrogen
compound
formula
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002204130A
Other languages
English (en)
Inventor
Christopher Walpole
Soo Young Ko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9425085.9A external-priority patent/GB9425085D0/en
Priority claimed from GBGB9426016.3A external-priority patent/GB9426016D0/en
Application filed by Individual filed Critical Individual
Publication of CA2204130A1 publication Critical patent/CA2204130A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composés de la formule (I) et leur sel d'addition d'acide; dans cette formule, R¿1? représente phényle mono ou disubstitué, n vaut zéro ou 1, X¿1? représente oxygène, soufre ou =NCN, X¿2? et X¿3? représentent oxygène ou soufre, R¿2? représente hydrogène ou méthyle, R¿3? représente phényle, phényle substitué par halo, 2-naphtyle, IH-indol-3-yle ou 1-méthyl-indol-3-yle, Z représente -N(CH¿3?)- ou -CH¿2?-, R¿4? représente phényle, 3,5-bis(trifluorométhyl)phényle ou pyridyle et R¿5? représente hydrogène, phényle 3,5-bis(trifluorométhyl)phényle ou pyridyle, étant entendu que lorsque X¿3? représente soufre, Z représente -N(CH¿3?)-. Ces composés possèdent une activité antagoniste par rapport à la tachykinine et ils sont utiles en tant que médicaments, par exemple dans le traitement de la douleur.
CA002204130A 1994-12-13 1995-12-12 Antagonistes de la tachykinine Abandoned CA2204130A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9425085.9 1994-12-13
GBGB9425085.9A GB9425085D0 (en) 1994-12-13 1994-12-13 Organic compounds
GB9426016.3 1994-12-22
GBGB9426016.3A GB9426016D0 (en) 1994-12-22 1994-12-22 Organic compounds

Publications (1)

Publication Number Publication Date
CA2204130A1 true CA2204130A1 (fr) 1996-06-20

Family

ID=26306161

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002204130A Abandoned CA2204130A1 (fr) 1994-12-13 1995-12-12 Antagonistes de la tachykinine

Country Status (17)

Country Link
EP (1) EP0797583A1 (fr)
JP (1) JPH10511935A (fr)
AR (1) AR001332A1 (fr)
AU (1) AU4343796A (fr)
BR (1) BR9509997A (fr)
CA (1) CA2204130A1 (fr)
CO (1) CO4700289A1 (fr)
CZ (1) CZ179097A3 (fr)
FI (1) FI971685A (fr)
HU (1) HUT77002A (fr)
IL (1) IL116323A0 (fr)
NO (1) NO972526L (fr)
PE (1) PE38997A1 (fr)
PL (1) PL320217A1 (fr)
SK (1) SK74697A3 (fr)
TR (1) TR199501568A2 (fr)
WO (1) WO1996018643A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
WO1998015277A2 (fr) * 1996-10-07 1998-04-16 Merck Sharp & Dohme Limited Antagoniste du recepteur nk-1 utilise comme antidepresseur et/ou agent anxiolytique
WO2000048623A1 (fr) 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Nouveaux derives amide secretagogues de l'hormone de croissance
KR101412339B1 (ko) 2004-07-15 2014-06-25 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
CN101495184A (zh) 2005-07-15 2009-07-29 Amr科技公司 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (fr) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
SI2805945T1 (sl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
WO2008090117A1 (fr) 2007-01-24 2008-07-31 Glaxo Group Limited Nouvelles compositions pharmaceutiques
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
CA2690191C (fr) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. Derives de 4-carboxybenzylamino utilises en tant qu'inhibiteurs de l'histone desacetylase
CA2717509A1 (fr) 2008-03-03 2009-09-11 Tiger Pharmatech Inhibiteurs de la tyrosine kinase
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
EP2413932A4 (fr) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibiteurs de l'activité akt
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
CA2760837C (fr) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et son utilisation
CA2777043C (fr) 2009-10-14 2015-12-15 Schering Corporation Piperidines substituees qui accroissent l'activite de p53, et utilisations de ces composes
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (fr) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
EP3766975A1 (fr) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2012143879A1 (fr) 2011-04-21 2012-10-26 Piramal Healthcare Limited Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation
EP2770987B1 (fr) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
WO2013165816A2 (fr) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. Compositions de petit acide nucléique interférent (sina)
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
ES2651347T3 (es) 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Composiciones y métodos para el tratamiento del cáncer
CA2895504A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituees en tant qu'inhibiteurs de hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785A4 (fr) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
JPH05186498A (ja) * 1991-12-27 1993-07-27 Japan Tobacco Inc プロリン誘導体

Also Published As

Publication number Publication date
SK74697A3 (en) 1997-11-05
BR9509997A (pt) 1997-12-30
HUT77002A (hu) 1998-03-02
AU4343796A (en) 1996-07-03
IL116323A0 (en) 1996-03-31
JPH10511935A (ja) 1998-11-17
NO972526D0 (no) 1997-06-03
CZ179097A3 (en) 1997-10-15
NO972526L (no) 1997-06-03
FI971685A0 (fi) 1997-04-18
CO4700289A1 (es) 1998-12-29
FI971685A (fi) 1997-08-13
WO1996018643A1 (fr) 1996-06-20
PL320217A1 (en) 1997-09-15
EP0797583A1 (fr) 1997-10-01
PE38997A1 (es) 1997-10-02
MX9703957A (es) 1997-09-30
TR199501568A2 (tr) 1996-07-21
AR001332A1 (es) 1997-10-22

Similar Documents

Publication Publication Date Title
CA2204130A1 (fr) Antagonistes de la tachykinine
KR100637110B1 (ko) 세포 유착 억제제
US4668769A (en) Oxa- and azahomocyclostatine polypeptides
US4599198A (en) Intermediates in polypeptide synthesis
US5559128A (en) 3-substituted piperidines promote release of growth hormone
AU726585B2 (en) Biarylalkanoic acids as cell adhesion inhibitors
JP5368089B2 (ja) Ｈｃｖインヒビター
SK5592003A3 (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
JP3817256B2 (ja) タキキニンアンタゴニスト
EP0644892A1 (fr) Inhibiteurs d'angiotensine i-chymase(s), comprenant la chymase cardiaque humaine
HU193671B (en) Process for producing benzazoninine derivatives and pharmaceutical compositions containing them as active agents
WO2008086053A1 (fr) Inhibiteurs du vhc
EP0933379B1 (fr) Nouveaux derives de peptides presentant un residu de thiazolyle-alanine
SE447389B (sv) Nya tripeptider, som inverkar pa det centrala nervsystemet
US6407065B1 (en) VLA-4 antagonists
US5714470A (en) Orally-active elastase inhibitors
US5478811A (en) Orally-active elastase inhibitors
JPH01163164A (ja) アミノ酸誘導体
MXPA97003957A (en) Antagonists of taquicin
HU203249B (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising same as active ingredient
JPH03148248A (ja) アミノ酸誘導体
MXPA00007186A (en) Vla-4 antagonists
WO2001042192A2 (fr) Antagonistes de l'integrine vla-4
JPH08325229A (ja) 新規なω−グアニジノ−Ｌ−α−アミノ酸アミド誘導体
JPH0441143B2 (fr)

Legal Events

Date Code Title Description
FZDE Discontinued